AbbVie Q4 Adjusted EPS $2.79 Beats $2.77 Estimate, Sales $14.30B Beat $14.02B Estimate
Portfolio Pulse from Benzinga Newsdesk
AbbVie (NYSE:ABBV) reported Q4 earnings of $2.79 per share, surpassing the $2.77 estimate, and sales of $14.30B, exceeding the $14.02B estimate. However, this represents a 22.5% decrease in earnings and a 5.42% decrease in sales from the same period last year.
February 02, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbbVie reported higher-than-expected Q4 earnings and sales, but saw a decrease compared to last year.
While AbbVie exceeded analyst expectations for Q4, the year-over-year decrease in both earnings and sales may temper investor enthusiasm. The positive earnings surprise could provide some short-term stock support, but the declines highlight potential challenges.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100